Compare MPLX LP (MPLX) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
MPLX LP vs TransMedics Group Inc — how do they compare? MPLX LP trades at $56.75 (market cap $57.97B), while TransMedics Group Inc trades at $74.3 (market cap $2.54B). The key difference: MPLX LP is far larger — about 22.8× TransMedics Group Inc's market cap, and MPLX LP pays a 7.54% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals.
| MPLX | TMDX | |
|---|---|---|
Market Cap | $57.97B | $2.54B |
Sector | Technology | Technology |
52-Week High | $59.17 | $150.42 |
52-Week Low | $47.80 | $61.99 |
Enterprise Value | $82.60B | $2.94B |
Dividend Yield | 7.54% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About MPLX LP
MPLX LP is a Master Limited Partnership (MLP) formed by Marathon Petroleum Corporation (MPC). It is a diversified, growth-oriented company primarily engaged in the gathering, processing, and transportation of natural gas and natural gas liquids (NGLs), as well as the transportation, storage, and distribution of crude oil and refined petroleum products. MPLX owns and operates a network of midstream energy infrastructure assets, providing essential services to the energy industry across the United States.
Read more on MPLX →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
